Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment

Completed

Conditions studied: Exudative Macular Degeneration

In brief

We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.

Key facts

Study ID

NCT02287298

Run by

The Retina Center of St. Louis County, PC

People needed

400

Starts

2014-08-01

Expected to finish

2015-12-01

Last updated by the study team

2016-04-06

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• MUST HAVE AGE RELATED MACULAR DEGENERATION

Where it is running

• The Retina Center — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.